Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Brown, Lauren E.
Devine, William G.
Porco, John A.
MetadataShow full item record
Accepted manuscriptSupporting documentation
Citation (published version)Xuan Zhang, Chengfeng Bi, Ting Lu, Weiwei Zhang, Ting Yue, Cheng Wang, Tian Tian, Xiaoyan Zhang, Yuhua Huang, Matthew Lunning, Xinbao Hao, Lauren E. Brown, William G. Devine, Julie Vose, John A. Porco, Kai Fu. 2020. "Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.." Leukemia, Volume 34, Issue 1, pp. 138 - 150. https://doi.org/10.1038/s41375-019-0503-z
MYC-driven lymphomas, especially those with concurrent MYC and BCL2 dysregulation, are currently a challenge in clinical practice due to rapid disease progression, resistance to standard chemotherapy, and high risk of refractory disease. MYC plays a central role by coordinating hyperactive protein synthesis with upregulated transcription in order to support rapid proliferation of tumor cells. Translation initiation inhibitor rocaglates have been identified as the most potent drugs in MYC-driven lymphomas as they efficiently inhibit MYC expression and tumor cell viability. We found that this class of compounds can overcome eIF4A abundance by stabilizing target mRNA-eIF4A interaction that directly prevents translation. Proteome-wide quantification demonstrated selective repression of multiple critical oncoproteins in addition to MYC in B-cell lymphoma including NEK2, MCL1, AURKA, PLK1, and several transcription factors that are generally considered undruggable. Finally, (-)-SDS-1-021, the most promising synthetic rocaglate, was confirmed to be highly potent as a single agent, and displayed significant synergy with the BCL2 inhibitor ABT199 in inhibiting tumor growth and survival in primary lymphoma cells in vitro and in patient-derived xenograft mouse models. Overall, our findings support the strategy of using rocaglates to target oncoprotein synthesis in MYC-driven lymphomas.